A Phase II study targeting amyloid-β with 3APS in mild-to-moderate Alzheimer disease

Abstract

Long-term administration of 3-amino-1-propanesulfonic acid is safe, tolerated and reduces CSF Abeta(42) levels in patients with mild-to-moderate Alzheimer disease.